Pressure BioSciences (PBIO) 10-Q 18 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	(508)
Local Phone Number	230-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,788,098

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 118,803	$ 132,311
Accounts receivable	291,846	154,746
Inventories, net of $342,496 reserve at March 31, 2022 and December 31, 2021	1,360,539	1,147,554
Prepaid expenses and other current assets	184,936	422,617
Total current assets	1,956,124	1,857,228
Investment in equity securities	79,114	59,976
Property and equipment, net	103,520	115,846
Right of use asset leases	369,006	395,565
Intangible assets, net	382,211	403,846
TOTAL ASSETS	2,889,975	2,832,461
CURRENT LIABILITIES
Accounts payable	665,228	527,924
Accrued employee compensation	170,212	117,680
Accrued professional fees and other	2,133,392	1,955,672
Other current liabilities	8,304,648	7,757,217
Deferred revenue	45,806	37,124
Convertible debt, net of unamortized discounts of $813,478 and $1,536,649, respectively	14,290,657	12,839,813
Other debt, net of unamortized discounts of $11,670 and $0, respectively	1,311,495	1,256,840
Operating lease liability	135,810	132,996
Other related party debt	195,250
Total current liabilities	27,252,498	24,625,266
LONG TERM LIABILITIES
Long term debt	150,000	150,000
Operating lease liability – long term	233,196	262,569
Deferred revenue	2,592	3,587
TOTAL LIABILITIES	27,638,286	25,041,422
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 10,194,136 and 9,120,526 shares issued and outstanding on March 31, 2022 and December 31, 2021 respectively	101,942	91,206
Warrants to acquire common stock	31,974,888	31,715,154
Additional paid-in capital	63,867,846	64,261,048
Accumulated deficit	(120,694,086)	(118,277,468)
Total stockholders’ deficit	(24,748,311)	(22,208,961)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	2,889,975	2,832,461
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	806	806
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	68	68
Series AA Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	$ 87	$ 87

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory Valuation Reserves	$ 342,496	$ 342,496
Other debt, unamortized discounts net	$ 11,670	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	10,194,136	9,120,526
Common Stock, Shares, Outstanding	10,194,136	9,120,526
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	300	300
Preferred stock, shares outstanding	300	300
Preferred stock, liquidation preference value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	80,570	80,570
Preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	21	21
Preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250	6,250
Preferred stock, shares issued	3,458	3,458
Preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,880	6,880
Preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,649	8,649
Preferred stock, shares outstanding	8,649	8,649
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 813,478	$ 1,536,649

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Products, services, other	$ 480,000	$ 559,874
Total revenue	480,000	559,874
Costs and expenses:
Cost of products and services	314,363	226,275
Research and development	281,589	299,943
Selling and marketing	66,462	93,328
General and administrative	903,885	1,015,430
Total operating costs and expenses	1,566,299	1,634,976
Operating loss	(1,086,299)	(1,075,102)
Other (expense) income:
Interest expense, net	(2,579,161)	(4,668,064)
Unrealized (loss) gain on investment in equity securities	19,138	(107,903)
Loss on extinguishment of liabilities	(589,850)	(725,159)
Other income (expense)	(3,513)	(1,359)
Total other expense	(3,153,386)	(5,502,485)
Net loss	(4,239,685)	(6,577,587)
Deemed dividends on beneficial conversion feature		(57,884)
Preferred stock dividends	(432,149)	(403,215)
Net loss attributable to common stockholders	$ (4,671,834)	$ (7,038,686)
Basic and diluted net loss per share attributable to common stockholders	$ (0.48)	$ (1.45)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	9,695,189	4,865,826

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,239,685)	$ (6,577,587)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on loan forgiveness	(10,000)	(367,039)
Non-cash lease expense	26,559	15,576
Common stock and warrants issued for interest and extension fees	1,173,458	2,622,078
Depreciation and amortization	35,096	27,190
Accretion of interest and amortization of debt discount	817,877	2,165,780
Loss on extinguishment of accrued liabilities and debt	589,570
Stock-based compensation expense	64,483	61,237
(Gain) loss on investment in equity securities	(19,138)	107,903
Common stock and warrants issued for services	117,461	238,512
Changes in operating assets and liabilities:
Accounts receivable	(137,100)	(373,268)
Inventories	(212,985)	33,402
Prepaid expenses and other assets	237,681	43,291
Accounts payable	137,304	(60,613)
Accrued employee compensation	52,532	42,702
Operating lease liability	(26,559)	(15,576)
Deferred revenue and other accrued expenses	637,164	799,397
Net cash used in operating activities	(756,282)	(1,237,015)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(1,135)	(3,962)
Net cash used in investing activities	(1,135)	(3,962)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from Series AA Convertible Preferred Stock		100,000
Proceeds from stock option exercises		14,773
Net proceeds from convertible debt	806,000	730,000
Net proceeds from non-convertible debt – third party	351,150	854,538
Net proceeds from non-convertible debt – related party	195,250	85,000
Payments on convertible debt	(324,350)	(191,250)
Payments on non-convertible debt – related party		(70,000)
Payments on non-convertible debt	(284,141)	(250,094)
Net cash provided by financing activities	743,909	1,272,967
NET INCREASE IN CASH AND CASH EQUIVALENTS	(13,508)	31,990
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	132,311	18,540
CASH AND CASH EQUIVALENTS AT END OF PERIOD	118,803	50,530
SUPPLEMENTAL INFORMATION
Interest paid in cash	120,436	37,375
NON CASH TRANSACTIONS:
Common stock issued with debt	142,480
Discount from warrants issued with debt	87,436	162,654
Common stock issued in lieu of cash for dividend	64,256
Early adoption of ASU 2020-06	473,027
Preferred stock dividends	432,149	403,215
Conversion of debt and interest into common stock	350,500	118,000
Discount due to beneficial conversion feature		53,777
Deemed dividend - beneficial conversion feature		$ 57,884

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholder's Deficit (Unaudited) - USD ($)	Series D Preferred Stock [Member]Preferred Stock [Member]	Series G Preferred Stock [Member]Preferred Stock [Member]	Series H Preferred Stock [Member]Preferred Stock [Member]	Series H2 Preferred Stock [Member]Preferred Stock [Member]	Series J Preferred Stock [Member]Preferred Stock [Member]	Series K Preferred Stock [Member]Preferred Stock [Member]	Series AA Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 41,683	$ 29,192,471	$ 50,312,968	$ (96,465,807)	$ (16,917,592)
Balance, shares at Dec. 31, 2020	300	80,570	10,000	21	3,458	6,880	8,043	4,168,324
Stock-based compensation										61,237		61,237
Series AA Preferred Stock dividend											(403,215)	(403,215)
Series AA Preferred Stock offering									49,884	50,116		100,000
Series AA Preferred Stock offering, shares							40
Beneficial conversion option on convertible preferred stock										57,884		57,884
Issuance of common stock for services								$ 1,124		237,388		238,512
Issuance of common stock for services, shares								112,400
Conversion of debt and interest for common stock								$ 472		117,528		118,000
Conversion of debt and interest for common stock, shares								47,200
Issuance of common stock for interest paid in kind								$ 9,224		2,012,556		2,021,780
Issuance of common stock for interest paid in kind, shares								922,372
Warrants issued with debt									162,654			162,654
Net loss											(6,577,587)	(6,577,587)
Stock option exercise								$ 214		14,559		14,773
Stock option exercise, shares								21,411
Issuance of warrants for interest paid-in-kind									600,298			600,298
Beneficial conversion feature on debt										53,777		53,777
Deemed dividend on convertible preferred stock										(57,884)		(57,884)
Ending balance, value at Mar. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 52,717	30,005,307	52,860,129	(103,446,609)	(20,527,363)
Ending balance, shares at Mar. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,083	5,271,707
Beginning balance, value at Dec. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 91,206	31,715,154	64,261,048	(118,277,468)	(22,208,961)
Balance, shares at Dec. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,649	9,120,526
Early adoption of ASU 2020-06										(2,728,243)	2,255,216	(473,027)
Stock-based compensation										64,483		64,483
Series AA Preferred Stock dividend											(432,149)	(432,149)
Issuance of common stock for services								$ 370		77,330		77,700
Issuance of common stock for services, shares								37,000
Issuance of common stock warrants for services									39,761			39,761
Warrants issued for debt extension									132,537			132,537
Warrants issued for debt extension, shares
Common stock issued for debt extension								$ 2,145		470,755		$ 472,900
Common stock issued for debt extension, shares								214,500				554,500
Conversion of debt and interest for common stock								$ 1,402		349,098		$ 350,500
Conversion of debt and interest for common stock, shares								140,200
Issuance of common stock for dividends paid-in-kind								$ 318		63,938		64,256
Issuance of common stock for dividends paid-in-kind, shares								31,810
Issuance of common stock for interest paid in kind								$ 5,581		1,167,877		1,173,458
Issuance of common stock for interest paid in kind, shares								558,100
Stock issued with debt								$ 920		141,560		142,480
Stock issued with debt, shares								92,000
Warrants issued with debt									87,436			87,436
Net loss											(4,239,685)	$ (4,239,685)
Stock option exercise, shares
Ending balance, value at Mar. 31, 2022	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 101,942	$ 31,974,888	$ 63,867,846	$ (120,694,086)	$ (24,748,311)
Ending balance, shares at Mar. 31, 2022	300	80,570	10,000	21	3,458	6,880	8,649	10,194,136

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure Biosciences, Inc. (“we”, “our”, “the Company”) develops and sells innovative, broadly enabling, high pressure-based platform technologies and related consumables for the worldwide life sciences, agriculture, food and beverage, and other key industries. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Historically, our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. In more recent years, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. On February 8, 2021, PBI announced plans to acquire the assets of a global eco-friendly agrochemical supplier. On April 14, 2021, PBI finalized terms and executed a new letter of intent to purchase the assets of the agrochemical supplier. This opportunity is attractive as it has the potential of readily producing significant revenue, as well as the potential to apply the UST technology to improve some of the product line. In July 2021, a newly-formed subsidiary of PBI, PBI Agrochem, leased a warehouse in Carson City, NV, and hired a warehouse manager.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of March 31, 2022, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past and as described in Notes 5 and 6. In addition we raised debt and equity capital after March 31, 2022 as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3) Summary of Significant Accounting Policies Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022. Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting companies financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended March 31, Primary geographical markets 2022 2021 North America $ 318 $ 208 Europe 46 84 Asia 116 268 $ 480 $ 560 Three Months Ended March 31, Major products/services lines 2022 2021 Hardware $ 284 $ 377 Consumables 40 102 Contract research services 15 6 Sample preparation accessories 31 29 Agrochem products 83 - Technical support/extended service contracts 17 24 Shipping and handling 10 19 Other - 3 $ 480 $ 560 Three Months Ended March 31, Timing of revenue recognition 2022 2021 Products transferred at a point in time $ 448 $ 538 Services transferred over time 32 22 $ 480 $ 560 Contract balances Schedule of Contract Balances In thousands of US dollars ($) March 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 292 $ 155 Contract liabilities (deferred revenue) 48 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 46 $ 3 $ 49 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended March 31, 2022 2021 Top Five Customers 73 % 88 % Federal Agencies 0 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. March 31, December 31, Top Five Customers 88 % 82 % Federal Agencies 3 % 5 % Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments. Investment in Equity Securities As of March 31, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of March 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 79,114 19,138 Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months ended March 31, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 For the Three Months Ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,671,834 ) $ (7,038,686 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 9,695,189 4,865,826 Loss per common share – basic and diluted $ (0.48 ) $ (1.45 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of March 31, 2022 2021 Stock options 1,307,822 1,358,490 Convertible debt 5,668,816 4,757,701 Common stock warrants 16,350,438 14,901,211 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,649,000 8,083,000 32,475,868 29,600,194 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 64,483 61,237 Schedule of Stock Based Compensation Expense For the Three Months Ended March 31, 2022 2021 Cost of sales $ 4,349 $ 5,053 Research and development 18,909 25,862 Selling and marketing 9,050 4,595 General and administrative 32,175 25,727 Total stock-based compensation expense $ 64,483 $ 61,237 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at March 31, 2022 using: March 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 79,114 $ 79,114 - - Total Financial Assets $ 79,114 $ 79,114 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 6,950 December 31, 2022 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term. The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12 Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 188,210 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 520,649 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 for the use of a lab bench, shared space and other utilities, and $ 2,000 per day for technical support services as needed. 60,000 in 2021 and $ 60,000 in 2022. ended March 31, 2022 and March 31, 2021, the Company reported $ 17,700 and $ 28,200 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the

Convertible Debt and Other Debt

Convertible Debt and Other Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	5) Convertible Debt and Other Debt Convertible Debt On various dates during the three months ended March 31, 2022, the Company issued convertible notes for a total of $ 1,114,738 which contained varied terms and conditions as follows: a) 5 - 12 month maturity date; b) interest rates of 12 %; c) convertible to the Company’s common stock at issuance at a fixed rate of $ 2.50 or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with either shares of common stock or warrants to purchase common stock that were fair valued at issuance date. The aggregate relative fair value of the shares of common stock and warrants issued with the notes of $ 229,916 was recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment at March 31, 2022. The specific terms of the convertible notes and outstanding balances as of March 31, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15,2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30,2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 March 1, 2022 6 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) $ - $ - July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 February 1, 2022 6 months $ 260,000 $ 210,000 $ 10,000 12 % $ (7 ) $ 2,000 $ - February 4, 2022 8 months $ 500,000 $ 500,000 $ 30,000 12 % $ (11 ) $ - $ - July 6, 2021 6 months $ 130,000 $ 130,000 $ 10,000 12 % $ 2.50 $ - $ - July 15, 2021 6 months $ 100,000 $ 45,000 $ 5,000 12 % (7 ) $ - $ 57,716 January 19, 2022 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 $ - January 20, 2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20, 2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20, 2022 6 months $ 140,875 $ 140,875 $ 18,375 (3 ) (8 ) $ - $ - August 31, 2021 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 Sept. 8, 2021 8 months $ 78,000 $ 78,000 $ 3,000 12 % (7 ) $ - $ 40,449 Sept. 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 108,801 Sept. 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 112,337 Sept. 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 118,650 $ 19,500 12 % (10 ) $ 3,750 $ - March 23,2022 8 months $ 56,500 $ 56,500 $ 6,500 12 % (12 ) $ - $ - March 29, 2022 8 months $ 112,000 $ 112,000 $ 13,000 12 % (12 ) $ - $ - February 9,2022 12 months $ 88,987 $ 80,112 $ 10,237 12 % (10 ) $ - $ - March 30, 2022 12 months $ 10,000 $ 10,000 $ - 12 % 2.50 $ - $ 38,400 $ 15,103,691 $ 1,703,088 $ 965,500 $ 8,460,529 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9% (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion. (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.50 25 (9) Conversion price of this note is $ 2.50 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 or the 10% (12) Notes are convertible at $ 2.50 75% (13) During the three months ended March 31, 2022, the Company extended two loans totaling $ 475,000 1,200,000 60,000 (14) During the three months ended March 31, 2022, the Company extended five loans totaling $ 1,045,000 1,107,251 149,500 As of March 31, 2022, one lender holds approximately $ 9.4 million of the $ 15.1 million convertible notes outstanding. For the three months ended March 31, 2022, the Company recognized amortization expense related to the debt discounts indicated above of $ 794,242 . The unamortized debt discounts as of March 31, 2022 related to the convertible debentures and other convertible notes amounted to $ 813,478 . Standstill and Forbearance Agreements In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. The Company and two lenders ($ 673,528 In connection to these agreements, the Company incurred interest, penalties, and fees of approximately $ 202,050 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the three months ended March 31, 2022 at substantially the same terms for extensions ranging over a period of three to six months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 0.6 The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2022: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2022 Balance at January 1, $ 12,839,813 Early adoption of ASU 2020-06 473,027 Issuance of convertible debt, face value 1,114,738 Deferred financing cost (308,738 ) Debt discount from shares and warrants issued with debt (229,916 ) Payments (324,350 ) Conversion of debt into equity (68,159 ) Accretion of interest and amortization of debt discount to interest expense 794,242 Balance at March 31, 14,290,657 Less: current portion 14,290,657 Convertible debt, long-term portion $ – Other Notes As of March 31, 2022 the Company owes $ 691,500 100,000 3 3.50 On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest. Merchant Agreements We have signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 10.8 % per month. As illustrated in the following table, under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the disclosed Daily Payment Rate. The Company’s Chief Executive Officer (“Guarantor”) is guaranteeing that the Company will perform its obligations under the Agreement. In no circumstance will Guarantor be asked or obligated to repay or be liable for the payment of any amount paid by Buyer to Seller, including, but not limited to, the The following table shows our Merchant Agreements as of March 31, 2022: Schedule of Merchant Agreements Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Deferred Finance Fees February 10, 2022 $ 120,000 $ 157,560 $ 67,285 Weekly 7,878.00 $ 1,200 January 11, 2022 $ 240,000 $ 300,000 $ 125,140 Weekly 11,112.00 $ - December 21, 2021 $ 400,000 $ 520,000 $ 268,775 Weekly 11,305.00 $ 6,000 $ 760,000 $ 977,560 $ 461,200 $ 7,200 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500 We have accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. Related Party Notes During the three months ended March 31, 2022, we received short-term non-convertible loans of $195,250 12% Long term debt The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75% $731 30

Stockholders_ Deficit

Stockholders’ Deficit	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Deficit	6) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 0.01 1,000,000 1) 20,000 Junior A 2) 313,960 Series A 3) 279,256 Series B 4) 88,098 Series C 5) 850 Series D 6) 500 (“Series E”) 7) 240,000 Series G 8) 10,000 Series H 9) 21 Series H2 10) 6,250 Series J 11) 15,000 Series K 12) 10,000 Series AA As of March 31, 2022, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2021 for the pertinent disclosures of preferred stock. Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 1,307,822 As of March 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 108,471 , which is expected to be recognized over weighted average period of 0.82 year. The aggregate intrinsic value associated with the options outstanding and exercisable, and the aggregate intrinsic value associated with the warrants outstanding and exercisable as of March 31, 2022, based on the March 31, 2022 closing stock price of $ 2.02 , was $ 1,707,483 . The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 230,000 3.50 230,000 - Exercised - - - - - - Expired/forfeited (25,279 ) 0.69 (86,670 ) $ 3.50 (111,949 ) - Balance outstanding, March 31, 2022 1,307,822 $ 0.72 16,350,438 $ 3.50 17,658,260 17,486,529 As of March 31, 2022, the 1,307,822 options outstanding have a $ 0.72 weighted average exercise price and 7.47 years weighted average remaining term. Of these options, 1,136,091 are currently exercisable. Common Stock and Warrant Issuances As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Defined Shares Issuable Loan Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly For the three-month period ended March 31,2022 the Company is obligated to issue 554,500 1,165,250 On various dates in the quarter ended March 31, 2022 the Company issued a total of 1,073,610 shares of restricted common stock to accredited investors and consultants. 140,200 of the shares with a fair value of $ 350,500 were issued for the conversion of debt and interest for common stock, 558,100 of the shares with a fair value of $ 1,173,458 were issued for interest paid-in-kind, 37,000 of the shares with a fair value of $ 77,700 were issued for services rendered, 31,810 shares with a fair value of $ 64,256 for dividends paid-in-kind, 92,000 shares with a fair value of $ 142,480 for new convertible debt issuances and 214,500 shares with a fair value of $ 472,900 for debt extension. During the three months ended March 31, 2022, we issued 100,000 warrants ( three -year term at a $ 3.50 exercise price) to acquire common stock at a fair value of $ 87,436 to a lender in conjunction with signing of new convertible loans. We also issued 30,000 warrants ( three 3.50 39,761 for services rendered and 100,000 warrants ( three 3.50 132,537 for debt extension. During the three months ended March 31, 2021, we issued 922,372 2.0 112,400 238,512 47,200 118,000 21,411 0.69 521,200 five 3.50 0.8

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events After April 1, 2022, the Company issued 22,000 200,000 12% 2.50 In this period, the Company also borrowed $ 227,000 10% 12% 211,000 225,000 11,008 40,000 20,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting companies financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended March 31, Primary geographical markets 2022 2021 North America $ 318 $ 208 Europe 46 84 Asia 116 268 $ 480 $ 560 Three Months Ended March 31, Major products/services lines 2022 2021 Hardware $ 284 $ 377 Consumables 40 102 Contract research services 15 6 Sample preparation accessories 31 29 Agrochem products 83 - Technical support/extended service contracts 17 24 Shipping and handling 10 19 Other - 3 $ 480 $ 560 Three Months Ended March 31, Timing of revenue recognition 2022 2021 Products transferred at a point in time $ 448 $ 538 Services transferred over time 32 22 $ 480 $ 560 Contract balances Schedule of Contract Balances In thousands of US dollars ($) March 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 292 $ 155 Contract liabilities (deferred revenue) 48 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 46 $ 3 $ 49 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended March 31, 2022 2021 Top Five Customers 73 % 88 % Federal Agencies 0 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. March 31, December 31, Top Five Customers 88 % 82 % Federal Agencies 3 % 5 %
Product Supply	Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.
Investment in Equity Securities	Investment in Equity Securities As of March 31, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of March 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 79,114 19,138
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months ended March 31, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 For the Three Months Ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,671,834 ) $ (7,038,686 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 9,695,189 4,865,826 Loss per common share – basic and diluted $ (0.48 ) $ (1.45 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of March 31, 2022 2021 Stock options 1,307,822 1,358,490 Convertible debt 5,668,816 4,757,701 Common stock warrants 16,350,438 14,901,211 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,649,000 8,083,000 32,475,868 29,600,194
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 64,483 61,237 Schedule of Stock Based Compensation Expense For the Three Months Ended March 31, 2022 2021 Cost of sales $ 4,349 $ 5,053 Research and development 18,909 25,862 Selling and marketing 9,050 4,595 General and administrative 32,175 25,727 Total stock-based compensation expense $ 64,483 $ 61,237
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at March 31, 2022 using: March 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 79,114 $ 79,114 - - Total Financial Assets $ 79,114 $ 79,114 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended March 31, Primary geographical markets 2022 2021 North America $ 318 $ 208 Europe 46 84 Asia 116 268 $ 480 $ 560 Three Months Ended March 31, Major products/services lines 2022 2021 Hardware $ 284 $ 377 Consumables 40 102 Contract research services 15 6 Sample preparation accessories 31 29 Agrochem products 83 - Technical support/extended service contracts 17 24 Shipping and handling 10 19 Other - 3 $ 480 $ 560 Three Months Ended March 31, Timing of revenue recognition 2022 2021 Products transferred at a point in time $ 448 $ 538 Services transferred over time 32 22 $ 480 $ 560
Schedule of Contract Balances	Contract balances Schedule of Contract Balances In thousands of US dollars ($) March 31, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 292 $ 155 Contract liabilities (deferred revenue) 48 41
Schedule of Future Related to Performance Obligations	Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 46 $ 3 $ 49
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended March 31, 2022 2021 Top Five Customers 73 % 88 % Federal Agencies 0 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. March 31, December 31, Top Five Customers 88 % 82 % Federal Agencies 3 % 5 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three months ended March 31, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 For the Three Months Ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,671,834 ) $ (7,038,686 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 9,695,189 4,865,826 Loss per common share – basic and diluted $ (0.48 ) $ (1.45 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of March 31, 2022 2021 Stock options 1,307,822 1,358,490 Convertible debt 5,668,816 4,757,701 Common stock warrants 16,350,438 14,901,211 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,649,000 8,083,000 32,475,868 29,600,194
Schedule of Stock Based Compensation Expense	Schedule of Stock Based Compensation Expense For the Three Months Ended March 31, 2022 2021 Cost of sales $ 4,349 $ 5,053 Research and development 18,909 25,862 Selling and marketing 9,050 4,595 General and administrative 32,175 25,727 Total stock-based compensation expense $ 64,483 $ 61,237
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at March 31, 2022 using: March 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 79,114 $ 79,114 - - Total Financial Assets $ 79,114 $ 79,114 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 188,210 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 520,649

Convertible Debt and Other De_2

Convertible Debt and Other Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of March 31, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15,2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30,2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 March 1, 2022 6 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) $ - $ - July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 February 1, 2022 6 months $ 260,000 $ 210,000 $ 10,000 12 % $ (7 ) $ 2,000 $ - February 4, 2022 8 months $ 500,000 $ 500,000 $ 30,000 12 % $ (11 ) $ - $ - July 6, 2021 6 months $ 130,000 $ 130,000 $ 10,000 12 % $ 2.50 $ - $ - July 15, 2021 6 months $ 100,000 $ 45,000 $ 5,000 12 % (7 ) $ - $ 57,716 January 19, 2022 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 $ - January 20, 2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20, 2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20, 2022 6 months $ 140,875 $ 140,875 $ 18,375 (3 ) (8 ) $ - $ - August 31, 2021 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 Sept. 8, 2021 8 months $ 78,000 $ 78,000 $ 3,000 12 % (7 ) $ - $ 40,449 Sept. 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 108,801 Sept. 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 112,337 Sept. 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 118,650 $ 19,500 12 % (10 ) $ 3,750 $ - March 23,2022 8 months $ 56,500 $ 56,500 $ 6,500 12 % (12 ) $ - $ - March 29, 2022 8 months $ 112,000 $ 112,000 $ 13,000 12 % (12 ) $ - $ - February 9,2022 12 months $ 88,987 $ 80,112 $ 10,237 12 % (10 ) $ - $ - March 30, 2022 12 months $ 10,000 $ 10,000 $ - 12 % 2.50 $ - $ 38,400 $ 15,103,691 $ 1,703,088 $ 965,500 $ 8,460,529 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9% (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion. (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.50 25 (9) Conversion price of this note is $ 2.50 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 or the 10% (12) Notes are convertible at $ 2.50 75% (13) During the three months ended March 31, 2022, the Company extended two loans totaling $ 475,000 1,200,000 60,000 (14) During the three months ended March 31, 2022, the Company extended five loans totaling $ 1,045,000 1,107,251 149,500
Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2022: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2022 Balance at January 1, $ 12,839,813 Early adoption of ASU 2020-06 473,027 Issuance of convertible debt, face value 1,114,738 Deferred financing cost (308,738 ) Debt discount from shares and warrants issued with debt (229,916 ) Payments (324,350 ) Conversion of debt into equity (68,159 ) Accretion of interest and amortization of debt discount to interest expense 794,242 Balance at March 31, 14,290,657 Less: current portion 14,290,657 Convertible debt, long-term portion $ –
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of March 31, 2022: Schedule of Merchant Agreements Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Deferred Finance Fees February 10, 2022 $ 120,000 $ 157,560 $ 67,285 Weekly 7,878.00 $ 1,200 January 11, 2022 $ 240,000 $ 300,000 $ 125,140 Weekly 11,112.00 $ - December 21, 2021 $ 400,000 $ 520,000 $ 268,775 Weekly 11,305.00 $ 6,000 $ 760,000 $ 977,560 $ 461,200 $ 7,200 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 230,000 3.50 230,000 - Exercised - - - - - - Expired/forfeited (25,279 ) 0.69 (86,670 ) $ 3.50 (111,949 ) - Balance outstanding, March 31, 2022 1,307,822 $ 0.72 16,350,438 $ 3.50 17,658,260 17,486,529
Schedule of Loans Obligated to Issue Shares	As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Defined Shares Issuable Loan Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Product Information [Line Items]
Revenue	$ 480,000	$ 559,874
Hardware [Member]
Product Information [Line Items]
Revenue	284,000	377,000
Consumables [Member]
Product Information [Line Items]
Revenue	40,000	102,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	15,000	6,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	31,000	29,000
Technical Support/Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	17,000	24,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	10,000	19,000
Others [Member]
Product Information [Line Items]
Revenue		3,000
Major Products Services Lines [Member]
Product Information [Line Items]
Revenue	480,000	560,000
Transferred at a Point in Time [Member]
Product Information [Line Items]
Revenue	448,000	538,000
Transferred Over Time [Member]
Product Information [Line Items]
Revenue	32,000	22,000
Timing Of Revenue Recognition [Member]
Product Information [Line Items]
Revenue	480,000	560,000
North America [Member]
Product Information [Line Items]
Revenue	318,000	208,000
Europe [Member]
Product Information [Line Items]
Revenue	46,000	84,000
Asia [Member]
Product Information [Line Items]
Revenue	116,000	268,000
Primary Geographical Markets [Member]
Product Information [Line Items]
Revenue	$ 480,000	$ 560,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 155	$ 292
Contract liabilities (deferred revenue)	$ 41	$ 48

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Mar. 31, 2022USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 49
2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	46
2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 3

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	73.00%	88.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	88.00%		82.00%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	0.00%	1.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	3.00%		5.00%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Net loss attributable to common stockholders	$ (4,671,834)	$ (7,038,686)
Weighted average common stock shares outstanding	9,695,189	4,865,826
Loss per common share – basic and diluted	$ (0.48)	$ (1.45)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	32,475,868	29,600,194
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,307,822	1,358,490
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	5,668,816	4,757,701
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	16,350,438	14,901,211
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	229,334	229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,649,000	8,083,000

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total stock-based compensation expense	$ 64,483	$ 61,237
Cost of Sales [Member]
Total stock-based compensation expense	4,349	5,053
Research and Development Expense [Member]
Total stock-based compensation expense	18,909	25,862
Selling and Marketing Expense [Member]
Total stock-based compensation expense	9,050	4,595
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 32,175	$ 25,727

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 79,114	$ 59,976
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	79,114	59,976
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	79,114	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	79,114	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 01, 2022	Dec. 31, 2021
Cumulative effect of adoption, adjustment in additional paid in capital	$ 63,867,846			$ 64,261,048
Cumulative effect of adoption, adjustment in accumulated deficit	$ (120,694,086)			$ (118,277,468)
Forfeiture rate	5.00%
Share based compensation	$ 64,483	$ 61,237
Nexity Global SA [Member]
Sale of Stock, Number of Shares Issued in Transaction	100,250
Investment owned fair value	$ 79,114
Marketable securities realized gain loss	$ 19,138
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative effect of adoption, adjustment in additional paid in capital			$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit			$ 2,255,216

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 188,210
2023	149,299
2024	64,393
2025	66,969
2026	51,778
Thereafter
Total	$ 520,649

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 09, 2021	Apr. 30, 2012	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease expire date			Dec. 30, 2023
Annua cost of living payment			$ 7,282
Lessee operating lease description	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term		The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees							$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees					$ 60,000	$ 60,000
Payments for fees		$ 1,400	$ 17,700	$ 28,200
Professional and contract services expense		$ 2,000
Medford lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Operating lease liability			$ 221,432
Estimated borrowing rate			12.00%
Sparks lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Operating lease liability			$ 239,327
Estimated borrowing rate			12.00%
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 6,950
Lease expire date			Dec. 31, 2022

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details)	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares
Line of Credit Facility [Line Items]
Convertible Debt	$ 14,290,657
Debt Conversion, Original Debt, Amount	68,159
Debt Instrument, Fee Amount	$ 7,200
Debt default convertible conversion ratio	75.00%
Five Loans [Member]
Line of Credit Facility [Line Items]
Proceeds from loan	$ 1,045,000
Debt Instrument, Increase (Decrease), Net	1,107,251
Fixed Rate Convertible Notes [Member]
Line of Credit Facility [Line Items]
Convertible Debt	15,103,691
Debt Conversion, Original Debt, Amount	1,703,088
Debt Instrument, Fee Amount	965,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 8,460,529
Convertible Notes One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 380,000
Convertible Debt	98,544
Debt Conversion, Original Debt, Amount	$ 15,200
Debt conversion interest rate percentage	8.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,200
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 332,407
Debt Conversion, Original Debt, Issuance Date of Debt	May 17, 2018	[1],[2]
Convertible Notes Two [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 2,500
Debt conversion interest rate percentage	24.00%
Conversion price | $ / shares	$ 7.50
Debt Instrument, Fee Amount	$ 2,500
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 3, 2019	[2],[3]
Convertible Notes Three [Member]
Line of Credit Facility [Line Items]
Term	9 months
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	302,484
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	8.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 40,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 70,631
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 4, 2019	[1],[2]
Convertible Notes Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 5,750
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 15,460
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 19, 2019	[1],[2]
Convertible Notes Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 3,750
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 13,759
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 27, 2019	[1],[2]
Convertible Notes Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 3,750
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 24, 2019	[1],[2]
Convertible Notes Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 385,000
Convertible Debt	320,000
Debt Conversion, Original Debt, Amount	$ 35,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,917
Debt Conversion, Original Debt, Issuance Date of Debt	Nov. 15, 2019	[2]
Convertible Notes Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 91,606
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 2, 2020	[2]
Convertible Notes Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 247,500
Convertible Debt	247,500
Debt Conversion, Original Debt, Amount	$ 22,500
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 22,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 89,707
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 24, 2020	[2]
Convertible Notes Ten [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 363,000
Convertible Debt	363,000
Debt Conversion, Original Debt, Amount	$ 33,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 33,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 297,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 29, 2020	[2]
Convertible Notes Eleven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 275,000
Convertible Debt	275,000
Debt Conversion, Original Debt, Amount	$ 25,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 25,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 225,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 12, 2020	[2]
Convertible Notes Twelve [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 135,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 19, 2020	[2]
Convertible Notes Thirteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 232,810
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 11, 2020	[2]
Convertible Notes Fourteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 60,705
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 13, 2020	[2]
Convertible Notes Fifteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 111,100
Convertible Debt	111,100
Debt Conversion, Original Debt, Amount	$ 10,100
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,100
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,900
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 26, 2020	[2]
Convertible Notes Sixteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 276,100
Convertible Debt	276,100
Debt Conversion, Original Debt, Amount	$ 25,100
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 25,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 221,654
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 8, 2020	[2]
Convertible Notes Seventeen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 143,750
Convertible Debt	143,750
Debt Conversion, Original Debt, Amount	$ 18,750
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 96,208
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 17, 2020	[2]
Convertible Notes Eighteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	546,250
Debt Conversion, Original Debt, Amount	$ 71,250
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 47,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 427,500
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 30, 2020	[2]
Convertible Notes Nineteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 460,000
Convertible Debt	460,000
Debt Conversion, Original Debt, Amount	$ 60,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 40,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 360,000
Debt Conversion, Original Debt, Issuance Date of Debt	May 6, 2020	[2]
Convertible Notes Twenty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	221,250
Debt Conversion, Original Debt, Amount	$ 46,250
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 439,500
Debt Conversion, Original Debt, Issuance Date of Debt	May 18, 2020	[2]
Convertible Notes Twenty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 902,750
Convertible Debt	652,750
Debt Conversion, Original Debt, Amount	$ 92,750
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 58,900
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 708,500
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 2, 2020	[2]
Convertible Notes Twenty Two [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 57,500
Convertible Debt	57,500
Debt Conversion, Original Debt, Amount	$ 7,500
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 5,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 45,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 12, 2020	[2]
Convertible Notes Twenty Three [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 138,000
Convertible Debt	138,000
Debt Conversion, Original Debt, Amount	$ 18,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 12,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 108,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 22, 2020	[2]
Convertible Notes Twenty Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 586,500
Convertible Debt	586,500
Debt Conversion, Original Debt, Amount	$ 76,500
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 51,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 400,234
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 7, 2020	[2]
Convertible Notes Twenty Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 362,250
Convertible Debt	362,250
Debt Conversion, Original Debt, Amount	$ 47,250
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 31,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 185,698
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 17, 2020	[2]
Convertible Notes Twenty Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Debt Conversion, Original Debt, Amount	$ 45,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 241,245
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 29, 2020	[2]
Convertible Notes Twenty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 24,875
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 21, 2020	[2],[4]
Convertible Notes Twenty Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 762,450
Convertible Debt	462,450
Debt Conversion, Original Debt, Amount	$ 69,450
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 66,300
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 580,124
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 14, 2020	[2]
Convertible Notes Twenty Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 391,000
Convertible Debt	391,000
Debt Conversion, Original Debt, Amount	$ 51,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 34,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 231,043
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 10, 2020	[2]
Convertible Notes Thirty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Debt Conversion, Original Debt, Amount	$ 45,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 66,375
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 21, 2020	[2],[4]
Convertible Notes Thirty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	15,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 20,500
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 23, 2020	[2],[4]
Convertible Notes Thirty Two [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 299,000
Convertible Debt	299,000
Debt Conversion, Original Debt, Amount	$ 39,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 26,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 197,882
Debt Conversion, Original Debt, Issuance Date of Debt	Dec. 3, 2020	[2]
Convertible Notes Thirty Three [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 18,875
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 22, 2020	[2],[4]
Convertible Notes Thirty Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 20,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 180,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 17, 2021	[2]
Convertible Notes Thirty Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 55,000
Convertible Debt	55,000
Debt Conversion, Original Debt, Amount	$ 5,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 36,431
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 23, 2021	[2]
Convertible Notes Thirty Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 402,500
Convertible Debt	402,500
Debt Conversion, Original Debt, Amount	$ 52,500
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 312,551
Debt Conversion, Original Debt, Issuance Date of Debt	May 6, 2021
Convertible Notes Thirty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 20,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 144,760
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 17, 2021
Convertible Notes Thirty Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 977,500
Convertible Debt	977,500
Debt Conversion, Original Debt, Amount	$ 127,500
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 773,802
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 25, 2021
Convertible Notes Thirty Nine [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 1,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 7,948
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 3, 2021	[2]
Convertible Notes Fourty [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 700,000
Convertible Debt	700,000
Debt Conversion, Original Debt, Amount	$ 84,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (6)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 1, 2022
Convertible Notes Fourty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 3, 2021
Convertible Notes Fourty Two [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 260,000
Convertible Debt	210,000
Debt Conversion, Original Debt, Amount	$ 10,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount	$ 2,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 1, 2022
Convertible Notes Fourty Three [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	500,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (11)	[5]
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 4, 2022
Convertible Notes Fourty Four [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 130,000
Convertible Debt	130,000
Debt Conversion, Original Debt, Amount	$ 10,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 6, 2021
Convertible Notes Fourty Five [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	45,000
Debt Conversion, Original Debt, Amount	$ 5,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 57,716
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 15, 2021
Convertible Notes Fourty Six [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 52,000
Convertible Debt	52,000
Debt Conversion, Original Debt, Amount	$ 2,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 2,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 19, 2022
Convertible Notes Fourty Seven [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 352,188
Convertible Debt	352,188
Debt Conversion, Original Debt, Amount	$ 45,938
Debt conversion interest rate percentage	(3.00%)
Conversion price | $ / shares	$ (8)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 20, 2022	[6]
Convertible Notes Fourty Eight [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 352,188
Convertible Debt	352,188
Debt Conversion, Original Debt, Amount	$ 45,938
Debt conversion interest rate percentage	(3.00%)
Conversion price | $ / shares	$ (8)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 20, 2022	[6]
Convertible Notes Fourty Nine [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 140,875
Convertible Debt	140,875
Debt Conversion, Original Debt, Amount	$ 18,375
Debt conversion interest rate percentage	(3.00%)
Conversion price | $ / shares	$ (8)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 20, 2022	[6]
Convertible Notes Fifty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	10.00%
Conversion price | $ / shares	$ (9)
Debt Instrument, Fee Amount	$ 16,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 148,500
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 31, 2021
Convertible Notes Fifty One [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 78,000
Convertible Debt	78,000
Debt Conversion, Original Debt, Amount	$ 3,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 40,449
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 8, 2021
Convertible Notes Fifty Two [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	100,000
Debt Conversion, Original Debt, Amount	$ 4,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 43,520
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 10, 2021
Convertible Notes Fifty Three [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 12,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 108,801
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 15, 2021	[2]
Convertible Notes Fifty Four [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 12,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 112,337
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 16, 2021	[2]
Convertible Notes Fifty Five [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 125,000
Convertible Debt	125,000
Debt Conversion, Original Debt, Amount	$ 6,250
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 61,876
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 24, 2021
Convertible Notes Fifty Six [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 37,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 15, 2021
Convertible Notes Fifty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 16,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 87,332
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 21, 2021	[4]
Convertible Notes Fifty Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 96,991
Debt Conversion, Original Debt, Issuance Date of Debt	Nov. 1, 2021	[4]
Convertible Notes Fifty Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 169,500
Convertible Debt	118,650
Debt Conversion, Original Debt, Amount	$ 19,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (10)
Debt Instrument, Fee Amount	$ 3,750
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Dec. 7, 2021
Convertible Notes Sixty [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 56,500
Convertible Debt	56,500
Debt Conversion, Original Debt, Amount	$ 6,500
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 23, 2022
Convertible Notes Sixty One [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 112,000
Convertible Debt	112,000
Debt Conversion, Original Debt, Amount	$ 13,000
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 29, 2022
Convertible Notes Sixty Two [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 88,987
Convertible Debt	80,112
Debt Conversion, Original Debt, Amount	$ 10,237
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ (10)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 9, 2022
Convertible Notes Sixty Three [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 10,000
Convertible Debt	10,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	12.00%
Conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 38,400
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 30, 2022
[1]	The Company and lenders have entered into Standstill and Forbearance Agreements (as described below).
[2]	The Note is past due. The Company and the lender are negotiating in good faith to extend the loan.
[3]	During the year ended December 31, 2020,
[4]	The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date.
[5]	Loans can be voluntarily converted before maturity at $ 2.50 2.50
[6]	Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9%

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) - USD ($)	Oct. 01, 2019	Mar. 31, 2022
Short-Term Debt [Line Items]
Debt instrument lowest trading price		25.00%
Debt Instrument, Description	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Debt instrument, convertible price per shares		$ 2.50
Debt Instrument, Convertible, Conversion Price		$ 2.50
Debt instrument conversion ratio		0.10
Shares issued, shares		554,500
Loans 2 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Description		Weekly
Proceeds from loans		$ 475,000
Increase in principal amount		$ 1,200,000
Loans 2 [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Shares issued, shares		60,000
Five Loans [Member]
Short-Term Debt [Line Items]
Proceeds from loans		$ 1,045,000
Increase in principal amount		$ 1,107,251
Five Loans [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Shares issued, shares		149,500
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Debt Instrument, Description		Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the
PBI Agrochem Inc [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price		40.90%

Summary of Changes in Convertib

Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
Balance at January 1,	$ 12,839,813
Early adoption of ASU 2020-06	473,027
Issuance of convertible debt, face value	1,114,738
Deferred financing cost	(308,738)
Debt discount from shares and warrants issued with debt	(229,916)
Payments	(324,350)
Conversion of debt into equity	(68,159)
Accretion of interest and amortization of debt discount to interest expense	794,242
Convertible Debt	14,290,657
Less: current portion	14,290,657
Convertible debt, long-term portion

Schedule of Merchant Agreements

Schedule of Merchant Agreements (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 760,000	$ 525,000
Purchased Amount	977,560	686,250
Outstanding Balance	461,200	398,910
Debt Instrument, Fee Amount	7,200	8,500
Merchant Agreements One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	120,000	400,000
Purchased Amount	157,560	520,000
Outstanding Balance	$ 67,285	$ 390,120
Debt Instrument, Frequency of Periodic Payment	Weekly	Weekly
Debt Instrument, Periodic Payment	$ 7,878	$ 11,305
Debt Instrument, Fee Amount	$ 1,200	$ 6,000
Inception date	Feb. 10, 2022	Dec. 21, 2021
Merchant Agreements Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 240,000	$ 125,000
Purchased Amount	300,000	166,250
Outstanding Balance	$ 125,140	$ 8,790
Debt Instrument, Frequency of Periodic Payment	Weekly	Daily
Debt Instrument, Periodic Payment	$ 11,112	$ 1,279
Debt Instrument, Fee Amount		$ 2,500
Inception date	Jan. 11, 2022	Jul. 6, 2021
Merchant Agreements Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 400,000
Purchased Amount	520,000
Outstanding Balance	$ 268,775
Debt Instrument, Frequency of Periodic Payment	Weekly
Debt Instrument, Periodic Payment	$ 11,305
Debt Instrument, Fee Amount	$ 6,000
Inception date	Dec. 21, 2021

Convertible Debt and Other De_3

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Oct. 01, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Short-Term Debt [Line Items]
Proceeds from convertible debt		$ 806,000	$ 730,000
Debt Instrument, Convertible, Conversion Price		$ 2.50
Convertible note outstanding		$ 14,290,657		$ 12,839,813
Debt Instrument, Fee Amount		7,200		$ 8,500
Gains losses on extinguishment of debt		(589,570)
Debt Instrument, Description	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Standstill and Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Convertible note outstanding		673,528
Debt Instrument, Fee Amount		$ 202,050
Economic Injury Disaster Loan Program [Member]
Short-Term Debt [Line Items]
Debt instrument, term		30 years
Debt instrument interest rate		3.75%
Debt Instrument, Face Amount		$ 150,000
Debt Instrument, Periodic Payment		731
One Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding		9,400,000
Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding		$ 15,100,000
Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 2.50
Convertible debt, fair value		$ 229,916
Maximum [Member] | Merchant Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate		10.80%
Convertible Debt [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt		$ 1,114,738
Amortization of Debt Discount (Premium)		$ 794,242
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, term		5 months
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, term		12 months
Debt instrument interest rate		12.00%
Convertible Debentures and Other Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt Instrument, Unamortized Discount		$ 813,478
New Loan [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate		10.00%
Gains losses on extinguishment of debt		$ 600,000
Notes 2 [Member] | Private Investor [Member]
Short-Term Debt [Line Items]
Debt owes		$ 691,500
Warrants issued		100,000
Warrants term		3 years
Warrants price		$ 3.50
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate		12.00%
Proceeds from short term debt		$ 195,250

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	17,540,209
Exercisable, beginning balance	17,308,567
Shares, granted	230,000
Shares, exercised
Shares, expired/forfeited	(111,949)
Shares, ending balance	17,658,260
Exercisable, ending balance	17,486,529
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	1,333,101
Weighted average price per share, beginning balance	$ 0.72
Shares, granted
Weighted average price per share, granted
Shares, exercised		(21,411)
Weighted average price per share, exercised
Shares, expired/forfeited	(25,279)
Weighted average price per share, expired/forfeited	$ 0.69
Shares, ending balance	1,307,822
Weighted average price per share, ending balance	$ 0.72
Exercisable, ending balance	1,136,091
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	16,207,108
Weighted average price per share, beginning balance	$ 3.50
Shares, granted	230,000
Weighted average price per share, granted	$ 3.50
Shares, exercised
Weighted average price per share, exercised
Shares, expired/forfeited	(86,670)
Weighted average price per share, expired/forfeited	$ 3.50
Shares, ending balance	16,350,438
Weighted average price per share, ending balance	$ 3.50

Schedule of Loans Obligated to

Schedule of Loans Obligated to Issue Shares (Details) - USD ($)	Oct. 01, 2019	Mar. 31, 2022
Short-Term Debt [Line Items]
Shares Issuable Frequency	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Loans 1 [Member]
Short-Term Debt [Line Items]
Loan Issuance Date		Jul. 21, 2020
Loan Principal		$ 115,000
Percentage of Loan Principal Issuable		0.0435%
Defined Date		Sep. 30, 2020
Shares Issuable Frequency		Monthly
Loans 2 [Member]
Short-Term Debt [Line Items]
Loan Issuance Date		Sep. 21, 2020
Loan Principal		$ 345,000
Percentage of Loan Principal Issuable		0.0362%
Defined Date		Nov. 16, 2020
Shares Issuable Frequency		Weekly
Loans 3 [Member]
Short-Term Debt [Line Items]
Loan Issuance Date		Oct. 22, 2020
Loan Principal		$ 115,000
Percentage of Loan Principal Issuable		0.0652%
Defined Date		Dec. 1, 2020
Shares Issuable Frequency		Weekly
Loans 4 [Member]
Short-Term Debt [Line Items]
Loan Issuance Date		Oct. 21, 2021
Loan Principal		$ 189,750
Percentage of Loan Principal Issuable		0.0435%
Defined Date		Jan. 2, 2022
Shares Issuable Frequency		Weekly
Loans 5 [Member]
Short-Term Debt [Line Items]
Loan Issuance Date		Nov. 1, 2021
Loan Principal		$ 189,750
Percentage of Loan Principal Issuable		0.0435%
Defined Date		Jan. 2, 2022
Shares Issuable Frequency		Weekly

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 30, 2021
Class of Stock [Line Items]
Option to acquire outstanding shares	17,658,260		17,540,209
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	17,486,529		17,308,567
Number of shares issued	554,500
Number of common stock conversion of debt and interest	$ 350,500	$ 118,000
Stock Issued During Period, Value, New Issues	472,900
Number of common stock for services rendered	$ 77,700	$ 238,512
Stock option exercise, shares
Lender [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Outstanding	100,000
Warrants term		3 years
Shares Issued, Price Per Share	$ 3.50
Fair value of warrants	$ 87,436
Services Rendered [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Outstanding	30,000
Warrants term		3 years
Shares Issued, Price Per Share	$ 3.50
Fair value of warrants	$ 39,761
Debt Extension [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Outstanding	100,000
Warrants term		3 years
Shares Issued, Price Per Share	$ 3.50
Fair value of warrants	$ 132,537
Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Number of shares issued	558,100
Stock Issued During Period, Value, New Issues	$ 1,173,458
Payment in Kind (PIK) Note [Member] | Lenders [Member]
Class of Stock [Line Items]
Number of shares issued		922,372
Stock Issued During Period, Value, New Issues		$ 2,000,000
Dividends Paid In Kind [Member]
Class of Stock [Line Items]
Number of shares issued	31,810
Stock Issued During Period, Value, New Issues	$ 64,256
Conversion of Debt Extension [Member]
Class of Stock [Line Items]
Number of common stock conversion of debt and interest, shares	140,200	47,200
Number of common stock conversion of debt and interest	$ 350,500	$ 118,000
Issued For Services Rendered [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares	37,000	112,400
Number of common stock for services rendered	$ 77,700	$ 238,512
New Conversion Debt [Member]
Class of Stock [Line Items]
Number of shares issued	92,000
Stock Issued During Period, Value, New Issues	$ 142,480
Debt Settlement [Member]
Class of Stock [Line Items]
Number of shares issued	214,500
Stock Issued During Period, Value, New Issues	$ 472,900
Accredited Investor [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	1,073,610
Stock Options [Member]
Class of Stock [Line Items]
Option to acquire outstanding shares	1,307,822		1,333,101
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.72		$ 0.72
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 19 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	1,136,091
Stock option exercise, shares		21,411
Stock options, exercise price		$ 0.69
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued	214,500
Interest expenses debt	$ 1,165,250
Number of common stock conversion of debt and interest, shares	140,200	47,200
Number of common stock conversion of debt and interest	$ 1,402	$ 472
Stock Issued During Period, Value, New Issues	$ 2,145
Number of common stock for services rendered, shares	37,000	112,400
Number of common stock for services rendered	$ 370	$ 1,124
Stock option exercise, shares		21,411
Warrant [Member]
Class of Stock [Line Items]
Option to acquire outstanding shares	16,350,438		16,207,108
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.50		$ 3.50
Number of common stock conversion of debt and interest
Stock Issued During Period, Value, New Issues
Number of common stock for services rendered
Stock option exercise, shares
Warrant [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Warrants term		5 years
Fair value of warrants		$ 800,000
Warrant issued		521,200
Warrant exercise price		$ 3.50
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 108,471
Unrecognized compensation, period	9 months 25 days
Share Price	$ 2.02
Aggregate intrinsic value of options outstanding and exerciasable	$ 1,707,483
2021 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance				3,000,000
Option to acquire outstanding shares	1,307,822
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, shares issued	1,000,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	20,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	313,960
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	279,256
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	88,098
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	850		850
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	300		300
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	500
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	240,000		240,000
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	80,570		80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	10,000		10,000
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	10,000		10,000
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	21
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	6,250		6,250
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	3,458		3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	15,000		15,000
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	6,880		6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	10,000		10,000
Convertible preferred stock, par value	$ 0.01		$ 0.01
Convertible preferred stock, shares issued	8,649		8,649

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 18, 2022	Mar. 31, 2022	Mar. 31, 2021	May 18, 2022
Subsequent Event [Line Items]
Value of convertible stock		$ 350,500	$ 118,000
Conversion price		$ 2.50
Due from related party		$ 195,250	85,000
Repayment of related party debt			$ 70,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of convertible shares issued	22,000
Value of convertible stock	$ 200,000
Interest rate	12.00%			12.00%
Conversion price	$ 2.50			$ 2.50
Due from related party				$ 227,000
Debt discount percentage	10.00%			10.00%
Repayment of related party debt	$ 211,000
Number od shares issued for service	40,000
Number of shares to be issued	20,000
Subsequent Event [Member] | Merchant cash loan agreement [Member]
Subsequent Event [Line Items]
Contractual payment	$ 225,000			$ 225,000
Periodic payment of contractual obligation	$ 11,008			$ 11,008